29 July 2020 - interim results
The group has reported interim results for the six months to 30 June and these have come in much as expected with revenue up 8% to £16.7bn with strong growth in consumer healthcare following the acquisition of the Pfizer portfolio. Adjusted pre-tax profits were 1% higher at £4.0bn and earnings per share on the same basis declined 6% to 56.9p. The interim dividend was maintained at 38p following a second quarterly dividend of 19p. The shares are not particularly exciting but on the basis that an 80p dividend is proposed for . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters. Get one week FREE trial with all our packages. Registration is quick and simple HERE.
Already a member, log in HERE.